The liver is the main organ having the key enzymes that regulate oxidative stress.[1,2] Ischemia/reperfusion (I/R) injury in the liver occurs after a prolonged period of ischemia followed by restoration of hepatic blood perfusion.[3] During the surgery of abdominal aorta, I/R injury causes damage to lower extremities and many organs, especially liver. The antioxidant and tumor necrosis factor-alpha (TNF-α) suppression effects of topiramate (TPM) have been reported in several studies. We evaluated the potential protective effect of TPM on cellular damage in liver tissue during I/R injury.

**Materials and Methods:** Thirty male Wistar albino rats were divided into three groups: Control, I/R, and I/R plus TPM (I/R + TPM) groups. Laparotomy without I/R injury was performed in the control group. After laparotomy, cross-ligation of infrarenal abdominal aorta was applied for 2 h in I/R groups that was followed by 2 h of reperfusion. TPM (100 mg/kg/day) was orally administrated to the animals in the I/R + TPM group for seven consecutive days before I/R procedure.

**Results:** The I/R group’s TNF-α and interleukin-6 (IL-6) levels were significantly higher than those of the control (P = 0.010; P = 0.002) and I/R + TPM groups (P = 0.010; P = 0.002, respectively). Asymmetric dimethyl arginine (ADMA) levels of I/R group were higher than the control (P = 0.015) and I/R + TPM groups. I/R caused serious histopathological damage to liver tissue; however, TPM led to very low histopathological changes.

**Conclusion:** Our data demonstrated that TPM treatment prominently decreases the severity of liver I/R injury. TPM pretreatment may have preventive effects on liver injury via I/R during intra-abdominal surgery.

**Key Words:** Asymmetric dimethyl arginine, carbonic anhydrase II, ischemia reperfusion, liver, topiramate
synthetase (NOS) enzyme for arginine.\textsuperscript{[14]} So inhibition of arginase leads to the elevation of NO level, on the contrary its overexpression leads to reduction of NO level, which increases asymmetric dimethyl arginine (ADMA).\textsuperscript{[15,16]} Carbonic anhydrase (CA)-II is a zinc metalloenzyme, which reversibly catalyzes the hydration reaction of CO\textsubscript{2} to form carbonic acid (H\textsubscript{2}CO\textsubscript{3}).\textsuperscript{[17]} This enzyme is found in many tissues, including liver. Overexpression of CA-II may lead to the formation of carbonate radicals.\textsuperscript{[18]} A previous study has shown TPM to be a very potent inhibitor of human CA-II.\textsuperscript{[19]}

In this study, we aimed to evaluate whether TPM prevents cellular damage during I/R and whether it has an effect on arginase-I and CA-II enzymes.

**MATERIALS AND METHODS**

In this study, we used 30 Wistar albino male rats weighing 250–300 g (12–15 weeks old). The rats were divided into three groups: An I/R group (n = 10), a TPM-preconditioned I/R group (n = 10), and a control group (n = 10). The study was approved by the institutional Ethics Committee (approval numbers: 2012/19).

Rats included in the control groups received saline solution. After the exploration of their abdominal aorta neither ischemia nor treatment was given to the rats of the control group. After the laparotomy of I/R group rats, infrarenal abdominal aorta (IAA) was clamped for 120 min then reperfusion was carried out for 120 min. TPM (100 mg/kg/day, Topamax\textregistered, Johnson and Johnson) was orally (via gastric gavage) given to I/R + TPM group for seven consecutive days before I/R.\textsuperscript{[20]} By the end of these seven days, 120 min of ischemia and 120 min of reperfusion was applied to I/R + TPM group.

**Aortic ischemia/reperfusion**

The I/R model was designed similar to the previous studies.\textsuperscript{[15]} Intraperitoneal injection of 50 mg/kg ketamine hydrochloride (Ketalar, 50 mg/kg intramuscularly; Eczacibasi, Istanbul, Turkey) was used to anesthetize the rats. The rats were placed supine on a heated mat in standard room conditions, then the surgery was performed. Ten milliliters per hour of sterile saline was injected subcutaneously into the neck of the rats to replace surgical fluid losses from evaporation. After performing a midline laparotomy, a minimum dissection of the retroperitoneum was made to expose the infrarenal aorta; then a microvascular clamp was placed across the IAA. After that the abdomen was closed and the wound was covered with plastic wrap to prevent the loss of heat and fluid. After 120 min, the microvascular clamp on the IAA was removed and the lower limb reperfusion was maintained for 120 min. Aortic occlusion and reperfusion was confirmed by observing the loss and reappearance of the pulsation on the distal aorta. After ending the reperfusion, a median sternotomy was performed and the blood samples were drawn from the right ventricles of all rats for biochemical analyses.

**Tissue homogenates**

The sample was homogenized in phosphate buffered solution (PBS), pH 7.4, and centrifuged at 10,000 g for 20 min and then the aliquot of the supernatant was put into tubes and frozen at −80°C. The parameters were examined within one month.

**Measurement of protein**

Tissue homogenate protein assay is a turbidimetric procedure that uses benzethonium chloride as a protein denaturing agent. A protein in the fine suspension is quantitated turbidimetrically at 404 nm (Architect c 16000, Abbott Laboratories, Illinois, USA).

**Tumor necrosis factor-α**

The level of TNF-α was measured by enzyme-linked immunosorbent assay (ELISA) method. We used commercially available rat TNF-α ELISA kit (eBioscience, Vienna, Austria). The ELISA method was applied according to the instructions provided by the manufacturer. Absorbance was measured at a wavelength of 450 nm using ELISA reader. The levels of TNF-α are expressed as pg/mL. The intra-assay and interassay coefficients of variation were <5% and <10%, respectively. The limit of detection (LOD) for the TNF-α assay was 11 pg/mL. When dividing the obtained values by protein levels, the final results were obtained as μmol/g protein. When dividing the values we have gotten by protein levels, the final results were obtained as μmol/g protein.

**Interleukin-6**

The level of IL-6 was measured by ELISA method. We used commercially available rat IL-6 ELISA kit (Invitrogen, CA, USA). The ELISA method was applied according to the instructions provided by the manufacturer. Absorbance was measured at a wavelength of 450 nm using ELISA reader. The levels of IL-6 are expressed as pg/mL. The intra-assay and interassay coefficients of variation were 3.5% and 6.3%, respectively. The LOD for the IL-6 assay was <5 pg/mL. When dividing the values we obtained by protein levels, the final results were expressed as μmol/g protein.

**Asymmetric dimethyl arginine**

The concentration of ADMA was measured using ELISA method. We used commercially available ADMA Elisa kit (DLD diagnostika GMBH, Hamburg, Germany). The ELISA method was applied according to the instructions provided by the manufacturer. Absorbance was measured...
at a wavelength of 450 μm using ELISA reader. The levels of ADMA are presented as μmol/L. The intra-assay and interassay coefficients of variation were 6.1% and 9.4%, respectively. The LOD for the ADMA assay was 0.05 μmol/L. When dividing the values we obtained by protein levels, the final results were expressed as μmol/g protein.

Biochemical parameters
The blood samples (10 mL) were collected into tubes. The blood was separated by centrifugation at 3000 rpm for 10 min after standing at room temperature for 15 min. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were checked by using the determined commercial kits (Architect c 16000, Abbott Laboratories, Illinois, USA).

Histologic evaluation
The liver tissue obtained from all the rat groups were given label code numbers and names of the group and then left in 10% neutral formaldehyde solution. After waiting in the fixative for 24 h, they were washed by streaming water for 4–6 h. After that they were dealt with ethanol–xylene (50%–100%) before being automated by tissue tracking (Citadel 2000, Thermo Fisher Scientific Shandon, England) and embedded in paraffin. Tissues were cut into 3–4 μm thick sections. The light microscopic examination was performed with different magnifications and appropriate views were photographed. Immunohistochemical staining steps started by cutting the tissues into 3–4 μm thick sections and followed by leaving them for 20 min in xylene before the application of alcohol series (50%–100%) then leaving them in 3% H2O2 solution for 10 min. After PBS washing, they were heated in citrate buffer solution by 800 W power for 4 × 5 min, then stand in secondary blocker substance for 20 min. Each slide was allowed to stand for 75 min in different dilutions of primary antibody (liver arginase 1 μg/mL and carbonic anhydrase-II 1/250–/500) before being stained by anticalcic anhydrase II (cod: ab124687, Abcam plc, Cambridge, UK) and anti-liver arginase antibody (Cod: ab91279, Abcam plc, Cambridge, UK). Diaminobenzidine solution was used as a chromogen and for counterstain, Mayer’s hematoxylin was applied for 3–5 min. We used PBS as a negative controller. Preparations were photographed after being covered with appropriate covering materials. Immunohistochemical staining preparations were categorized into four items according to the tissues percentage of immunopositive reaction areas as mild (+), moderate (+++), severe (+++), and very severe (++++) . The blocked tissues were cut into 4–5 μm thick sections before being stained by hematoxylin and cosin (H and E). All histologists slides were reviewed by two histologist who were blinded for the rat groups.

Statistical analyses
The results are presented as mean ± SD. The Kruskal–Wallis test was used to compare the groups. A Bonferroni adjusted Mann–Whitney U test was used to compare the two groups. Statistically significant differences were obtained at a P value of less than 0.05.

RESULTS
Biochemical parameters
The I/R group’s TNF-α levels (428.7 ± 95.9 pg/mg protein) were significantly higher than those of the control (358.8 ± 48.6 pg/mg protein, P = 0.010) and I/R + TPM groups (353.3 ± 55.3 pg/mg protein, P = 0.010). I/R group’s IL-6 levels (569.0 ± 91.7 pg/mg protein) were significantly higher than those of the control (443.6 ± 44.6 pg/mg protein, P = 0.002) and I/R + TPM groups (454.4 ± 39.9 pg/mg protein, P = 0.002). I/R group’s ADMA levels (0.05 ± 0.002 μmol/g protein) were significantly higher than those of the control (443.6 ± 44.6 pg/mg protein, P = 0.002) and I/R + TPM groups (0.03 ± 0.007 μmol/g protein) but were not statistically significant. The control group’s AST levels (43.8 ± 5.3 IU/L) were significantly higher than those of the I/R (73.5 ± 10.0 IU/L, P < 0.001) and I/R + TPM groups (0.05 ± 0.007 μmol/g protein) but were not statistically significant. The control group’s ALT levels (443.6 ± 44.6 pg/mg protein) were significantly higher than those of the control (443.6 ± 44.6 pg/mg protein, P = 0.002) and I/R + TPM groups (0.03 ± 0.007 μmol/g protein) but were not statistically significant. The all the results of biochemical parameters are shown in table 1.

Histologic evaluation
No textural or cellular deformity has been found in the histopathological examination of the liver tissue of the control group animals stained by immunohistochemical and H and E methods. The morphologic structures of the cells and tissues were observed to have normal histologic appearance [Figure 1a and Table 2].

Hepatocellular necrosis, cellular damage with intensive degenerations, and cellular loss were observed in the histopathological examination of the I/R group animals

| Parameters | Control | I/R | I/R+TPM |
|------------|---------|-----|---------|
| AST IU/L   | 43.8±5.3 | 73.5±10.0* | 66.0±6.9* |
| ALT IU/L   | 41.4±9.7 | 58.0±11.8* | 53.6±10.0 |
| TNF-α pg/mg protein | 358.8±48.6 | 428.7±95.9* | 353.3±55.3 |
| IL-6 pg/mg protein | 443.6±44.6 | 569.0±91.7* | 454.4±39.9 |
| ADMA μmol/g protein | 0.02±0.001 | 0.05±0.002* | 0.03±0.007 |

*P<0.001, **P<0.002, ***P<0.006, ****P<0.010, V*P<0.015 vs. control group, ¥P<0.002, ¥CP<0.010 vs. I/R+TPM group

Table 1: Biochemical results of the three groups
stained by H and E method [Figure 1b]. In the acute phase of reperfusion, there was intensive vasoconstriction related to degenerations and vacuolization of muscles of the vessel walls. Many histopathologic changes have been demonstrated in the portal region and adjacent sinusoids including an increase in leukocytes, scattered platelet aggregation in the sinusoids, endothelial cells swelling related to intracellular edema, and cellular shedding. Additionally, there were projections and recess deformities on the surface of endothelial and Kupffer cells, intensive vacuolization of vessel wall myocytes, and cellular degenerations. Eosinophil granulocytes and neutrophil granulocyte infiltrations were detected around the large vessels of the portal area. There were partial dilatations of the sinusoidal walls and Kupffer cells were rounded, flat, and bulging with protrusion into the lumen. There were intense necrotic cells and shedding related to hepatocyte degenerations in both central vein and portal regions. In acute phase, there was an increase in the number of neutrophil granulocytes in the connective tissue surrounding the areas of severe congestion in liver capillaries [Figure 1b and Table 2].

The histopathological examination after H and E stain method in ischemic reperfusion and TPM applied group revealed lower tissue and cellular deformity than ischemic reperfusion group [Table 1 and Figure 1c]. The intensive sinusoidal dilatations of I/R group were lower in the control group. However, the two groups have similar elongated sinusoidal structures. When compared with the I/R group, Kupffer cells settling the sinusoidal walls were observed to be more flat and stained deep basophilic. Vacuolization of the hepatocytes were lower in this group. However, they were observed around the portal region [Figure 1c]. The immunopositivity of CA-II in the hepatic tissues of the control and application groups was more intensively positive in sinusoidal walls and in the surroundings of the central vein. Although there was a decrease in immunoreactivity in progress to portal regions, it had a continuous course. Although immunoreactivity of the control group showed homogeneous distribution, it showed a decrease in the homogeneity and positivity when moving away from the central vein in the application group [Figure 2]. The immunopositivity of antiliver arginase in the hepatic tissues of the control group has low immunoreactivity in the surroundings of central vein. Although there was a decrease in immunoreactivity in progress to portal regions, it was lower in the periphery of the portal region. There was an extreme decrease in the antiliver arginase immunoreactivity [20% (+)] in necrotic and degenerative hepatocytes [Figure 3]. Histopathological results are shown in Table 2.

**DISCUSSION**

In our study, TNF-α, IL 6, and ADMA levels in the hepatic tissue from the I/R group were higher than both the control and TPM applied groups. TNF-α and IL-6 levels were found to be similar in the TPM applied group and the control group. In the I/R group, the levels of AST and ALT were high. AST, ALT, and tissue ADMA levels of TPM applied group were lower than those of the I/R group. The examined tissue stained by H and E revealed intensive cellular damage in I/R group, contrary to TPM applied group, which had lower cellular damage. In the tissues stained immunohistochemically, arginase and CPS-1 enzyme activities of I/R group were strongly higher than TPM applied group. Although the inflammatory cytokine levels of I/R group were obviously higher with intense histopathological damage, TPM group had lower histopathological damage with inflammatory cytokines level similar to the control group.

**Table 2: Histopathological results of the three groups**

|                      | Mean±sd         |
|----------------------|-----------------|
|                      | Control         | I/R group       | I/R+TPM group    |
| Cell loss            | 1.2±0.6         | 2.9±0.7*        | 1.9±0.3*         |
| Vacuolization        | 0±0             | 2.9±0.7**       | 2.1±0.3*         |
| Hepatocyte degeneration | 0.8±0.4        | 3.2±0.4**       | 2.2±0.6*         |
| Sinusoid dilatation  | 0±0             | 3.2±0.4**       | 1.8±0.4*         |
| Lymphocytes infiltration | 0±0             | 2.8±0.4**       | 1.2±0.4*         |
| Antiliver arginase reactivity | 2.0±0.5       | 3.3±0.8**       | 2.2±0.8          |
| Anti-CA-II reactivity | 2.0±0.7         | 3.4±0.5**       | 2.4±0.7          |

I/R: Ischemia/reperfusion, TPM: Topiramate, CA: Carbonic anhydrase. *P<0.001, **P<0.001, ***P<0.002 vs. control group. #P<0.001, $P<0.001, \#P=0.003, \$P=0.011 vs. I/R+TPM group.
NO as a vasodilator may maintain perfusion and prevent endothelial injury. It can accept other electrons as a free-radical scavenger. However, an excessive production of NO, especially by NOS is cytotoxic and may produce toxic peroxynitrite via its reaction with superoxide. NO is synthesized from arginine. The extensive production of ADMA could deteriorate the balance between NO and endothelin leading to vasoconstriction that affects the liver functions under I/R. It has been reported that ADMA as an inhibitor may have a role in overproduction of NO mainly by regulating NOS activity. Similar results have reported that in various pathological conditions there was an increase in ADMA level and a decrease in arginine level. NO inhibits the proliferation of liver tissues and adhesion of monocytes and leukocytes to endothelium. Additionally, it acts as an inhibitor by lowering vascular production of superoxide radicals leading to decreased low-density lipoprotein oxidation. ADMA itself may lead to severe endothelial dysfunction. The release of ADMA from an ischemic organ during the reperfusion stage competes with arginine for the active binging site in the center of NOS. NO inhibits the proliferation of liver tissues and adhesion of monocytes and leukocytes to endothelium. Additionally, it acts as an inhibitor by lowering vascular production of superoxide radicals leading to decreased low-density lipoprotein oxidation. ADMA itself may lead to severe endothelial dysfunction. The release of ADMA from an ischemic organ during the reperfusion stage competes with arginine for the active binging site in the center of NOS.

Arginase inhibitors have been shown to have a preventive effect in experimental I/R models. The inhibition of arginase during ischemia increases NO level, which leads to vasodilatation and lower ischemic damage. In our study, arginase enzyme activities and ADMA level were high in the I/R group. High levels of arginase and ADMA inhibit NOS enzyme ending in low NO level that may lead to severe vasoconstriction. Arginase level in the TPM group was similar to the control group, and ADMA level was lower. TPM treatment during I/R inhibits arginase, which may maintain the balance of NO level and prevent the increase of ADMA. CA is a ubiquitous metalloenzyme, which catalyzes the hydration reaction of carbon dioxide to bicarbonate. CA-II is abundant in many tissues, including the liver. It is responsible for catalyzing the reversible reaction between carbon dioxide and bicarbonate.

Overexpression of CA-II increases Cl⁻/HCO₃⁻ exchange activity, which increases intracellular bicarbonate, which leads to carbonate radicals. A previous study has shown that the reaction of nitrogen dioxide and carbonate radicals with carbohydrates and proteins could form a number of nitration and nitrosation products in the endothelial cells of the vessels during reperfusion injury. A previous study has shown peroxymonocarbonate, which was released from a spontaneous reaction of bicarbonate with H₂O₂, to be an intermediate metabolite of superoxide dismutase and peroxidase and a precursor of carbonate radical anions. Our study has shown that high CA-II enzyme activity in I/R group indicates a high carbonate radical leading to liver tissue damage. TPM treatment may decrease carbonate radical by preventing overexpression of CA-II enzyme.
During the early phase of I/R, hepatocytes are damaged by lipid peroxidation, protein oxidation, mitochondrial dysfunction, and DNA damage. Previous studies have shown that TNF-α and IL-6, which are responsible for apoptotic pathway activation, to be elevated during I/R. In our study, intensive release of TNF-α and IL-6 was observed in I/R group, whereas these cytokines were suppressed in TPM group and their levels were similar to those in the control group. The current study has shown that increased production of TNF-α and IL-6 during I/R may lead to strong oxidative stress and severe cellular damage. TNF-α suppressive effect of TPM is known. Our study has shown TPM to prevent liver tissue damage by reducing cytokine release during I/R. ALT and AST levels may increase due to liver tissue damage. The lower damage seen in TPM applied group may be related to the antioxidant effect of TPM that may decrease the production of pro-inflammatory cytokine and prevent I/R-induced liver tissue damage. Additionally, it may decrease I/R injury by the inhibition of cytokine release and maintenance of NO balance.

In our study, there were intensive histopathological changes observed in the liver tissue of I/R group such as cell loss, degeneration, vacuolization, sinusoidal dilatation, and lymphocytic infiltration. Histopathological damage of TPM applied group was obviously lower than I/R group. Neutrophil and macrophage infiltration has an important role in I/R damage. In this study, we did not use special stain for macrophages as this study is a pilot study and the present findings support the preventive effect of TPM against I/R injury. Additionally, in this study there was no intensive infiltration of neutrophils. I/R injury can be caused by many mechanisms. In addition, lymphocytes also are known to cause severe liver damage. Our results confirmed that TPM significantly reduce lymphocyte accumulation in I/R injury. Also, elevated levels of cytokines and peroxynitrite that lead to reactive oxygen species formation are in the forefront in the present study.

CONCLUSION

Overproduction of cytokines during I/R leads to liver tissue damage. High or low levels of NO can lead to tissue damage. TPM treatment decreases liver damage during I/R injury through a preventive effect by maintaining the balance of tissue NO level and antioxidant effect by decreasing cytokines release.

REFERENCES

1. Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997;276:60-6.
2. Mato JM, Corrales FJ, Lu SC, Avila MA. S-Adenosylmethionine: A control switch that regulates liver function. FASEB J 2002;16:15-26.
3. Aydogan MS, Ergodan MA, Polat A, Yücel A, Ozgül U, Paralakpinar H, et al. Protective effects of melatonin and β-d-Glucan against liver injury in rats a comparative study. Adv Clin Exp Med 2013;22:621-7.
4. Kaçmaz A, User EY, Sehirli AO, Tiliki M, Ozkan S, Sener G. Protective effect of melatonin against ischemia/reperfusion-induced oxidative remote organ injury in the rat. Surg Today 2005;35:744-50.
5. Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury: Present concepts. J Gastroenterol Hepatol 2011;26:173-9.
6. Peralta C, Brenner C. Endoplasmic reticulum stress inhibition enhances liver tolerance to ischemia/reperfusion. Curr Med Chem 2011;18:2016-24.
7. Peralta C, Jimenez-Castro MB, Gracia-Sancho J. Hepatic ischemia and reperfusion injury: Effects on the liver sinusoidal milieu. J Hepatol 2013;59:1094-106.
8. Hanaoka J, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, et al. Beneficial effects of enteral nutrition containing with hydrolyzed whey peptide on warm ischemia/reperfusion injury in the rat liver. Hepato Res 2014;44:114-21.
9. Sommer BK, Mitchell EL, Wroolie TE. Topiramate: Effects on cognition in patients with epilepsy, migraine headache and obesity. Ther Adv Neurol Disord 2013;6:211-27.
10. Nazzroglu M, Yurekli VA. Effects of antiepileptic drugs on antioxidant and oxidant molecular pathways: Focus on trace elements. Cell Mol Neurobiol 2013;33:589-99.
11. Himmerich H, Bartsch S, Hamer H, Mergl R, Schönherr J, Petersein C, et al. Impact of mood stabilizers and antiepileptic drugs on cytokine production in-vitro. J Psychiatr Res 2013;47:1751-9.
12. El-Abhar HS, Schaalen MF. Topiramate-induced modulation of hepatic molecular mechanisms: An aspect for its anti-insulin resistant effect. PLoS One 2012;7:e37757.
13. Sin YY, Ballantyne LL, Mukherjee K, St Amand T, Kyriakopoulou L, Schulze A, et al. Inducible arginase 1 deficiency in mice leads to hyperargininemia and altered amino acid metabolism. PLoS One 2013;8:e80001.
14. Esteweze AG, Sahavneh MA, Lange PS, Bae N, Egea M, Ratan RR. Arginase I regulation of nitric oxide production is key to survival of trophic factor-deprived motor neurons. J Neurosci 2006;26:8512-6.
15. Cure E, Cure MC, Tumkaya L, Kalkan Y, Aydin I, Kirbas A, et al. Adalimumab Ameliorates Abdominal Aorta Cross Clamping Which Induced Liver Injury in Rats. Biomed Res Int 2014;2014:907915.
16. Böger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor. J Nutr 2004;134:2842-7.
17. Al-Samir S, Papadopoulos S, Scheibe DJ, Meißner JD, Cartron JP, Syl WS, et al. Activity and distribution of intracellular carbonic anhydrase II and their effects on the transport activity of anion exchanger AE1/SLC4A1. J Physiol 2013;591:4963-82.
18. Medinas DB, Cerchiaro G, Trindade DF, Augusto O. The carbonic radical and related oxidants derived from bicarbonate buffer. IUBMB Life 2007;59:255-62.
19. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000;41:35-9.
20. Armagan A, Kutluhan S, Yılmaz M, Yılmaz N, Bülbül M, Vural H, et al. Topiramate and vitamin E modulate antioxidant enzyme activities, nitric oxide and lipid peroxidation levels in pentylenetetrazol-induced nephotoxicity in rats. Basic Clin Pharmacol Toxicol 2008;103:166-70.
21. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007;87:315-424.
23. Trocha M, Merwid-Lad A, Szuba A, Chlebda E, Piesziewska M, Sozanski T, et al. Effect of simvastatin on nitric oxide synthases (eNOS, iNOS) and arginine and its derivatives (ADMA, SDMA) in ischemia/reperfusion injury in rat liver. Pharmacol Rep 2010;62:343-51.

24. Dimitrow PP, Undas A, Bober M, Tracz W, Dubiel JS. Plasma biomarkers of endothelial dysfunction in patients with hypertrophic cardiomyopathy. Pharmacol Rep 2007;59:715-20.

25. Martin-Sanz P, Olmedilla L, Dulín E, Casado M, Callejas NA, Perez-Pena J, et al. Presence of methylated arginine derivatives in orthotopic human liver transplantation: Relevance for liver function. Liver Transpl 2003;9:40-8.

26. Steppan J, Nyhan D, Berkowitz DE. Development of Novel Arginase Inhibitors for Therapy of Endothelial Dysfunction. Front Immunol 2013;4:278.

27. Jeyabalan G, Klune JR, Nakao A, Martik N, Wu G, Tsung A, et al. Arginase blockade protects against hepatic damage in warm ischemia-reperfusion. Nitric Oxide 2008;19:29-35.

28. Boone CD, Pinard M, McKenna R, Silverman D. Catalytic Mechanism of α-Class Carbonic Anhydrases: CO2 Hydration and Proton Transfer. Subcell Biochem 2014;75:31-52.

29. Sterling D, Brown NJ, Supuran CT, Casey JR. The functional and physical relationship between the DRA bicarbonate transporter and carbonic anhydrase II. Am J Physiol Cell Physiol 2002;283:1522-9.

30. Hoffmann KM, Samarudic D, Heever KV, Rowelett KS. Co (II)-substituted Haemophilus influenzae β-carbonic anhydrase: Spectral evidence for allosteric regulation by pH and bicarbonate ion. Arch Biochem Biophys 2011;511:80-7.

31. Aljuhani N, Michail K, Karapetyan Z, Siraki AG. The effect of bicarbonate on menadione-induced redox cycling and cytotoxicity: Potential involvement of the carbonate radical. Can J Physiol Pharmacol 2013;91:783-90.

32. Queliconi BB, Marazzi TB, Vaz SM, Brookes PS, Nehrke K, Augusto O, et al. Bicarbonate modulates oxidative and functional damage in ischemia-reperfusion. Free Radic Biol Med 2013;55:46-53.

33. Martin-Sanz P, Olmedilla L, Dulín E, Casado M, Callejas NA, Perez-Pena J, et al. Presence of methylated arginine derivatives in orthotopic human liver transplantation: Relevance for liver function. Liver Transpl 2003;9:40-8.

34. Ocuin LM, Zeng S, Cavnar MJ, Sorenson EC, Bamboat ZM, Greer JB, et al. Nilotinib protects the murine liver from ischemia/reperfusion injury. J Hepatol 2012;57:766-73.

35. Kalogeris T, Baines CF, Krenz M, Korthuis RJ. Cell biology of ischemia/ reperfusion injury. Int Rev Cell Mol Biol 2012;298:229-317.

36. Linfert D, Chowdhry T, Rabb HT. Lymphocytes and ischemia-reperfusion injury. Transplant Rev (Orlando) 2009;23:1-10.

Source of Support: Nil, Conflict of Interest: None declared.